Status: Recruiting
Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy
This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.
Participants needed: 40
Trial details
Phase: Phase 1Age: 5-17Biological sex: AllType: InterventionalSponsor: Children's Mercy Hospital Kansas CityUpdated: Jun 24, 2026Locations: 1
Eligibility criteria
Ages 5-17 years of age [+3]
Previously or currently taking trihexyphenidyl [+2]